Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:37:48 2024-05-31 am EDT 5-day change 1st Jan Change
89.76 EUR +1.34% Intraday chart for Sanofi -0.44% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CAC40: at the 8000 pts threshold, loses nearly 1.3% over the week CF
CAC40: remains at equilibrium despite sharp decline in Nasdaq and S&P CF
CAC40: May ends with no trend and a zero score CF
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT
Sanofi: launch of employee share ownership plan 2024 CF
CAC40: stable trend before US inflation CF
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months MT
Sanofi: positive opinion from the CHMP in COPD CF
CAC40: slightly positive bias before the opening CF
US FDA Delays Decision on Sanofi, Regeneron's Lung Disease Treatment Dupixent MT
Sanofi, Regeneron's Lung Disease Treatment Recommended for EU Approval MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S. DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation CI
CAC40: regains some altitude, Airbus in support CF
Sanofi Closes Purchase of US Biotech Company Inhibrx MT
Sanofi: acquisition of Inhibrx finalized CF
Sanofi Opens New Advanced Vaccines Facility, Strengthening Its Commitment to Biomanufacturing in Canada CI
EU okays $1.5 bln state funded joint hydrogen project, $1.1 bln joint healthcare project RE
Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa MT
Sanofi: FDA grants priority review in myeloma CF
Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma CI
US, European nations consider vaccinating workers exposed to bird flu RE
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi MT
Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.76 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.53%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi to Invest $1.08 Billion Into 3 French Drug Manufacturing Sites